Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
KNSA Kiniksa Pharmaceuticals Ltd
- Stocks
- Healthcare
- NASDAQ: KNSA
Price (delayed)
$26.72
Market cap
$1.95B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.24
Enterprise value
$1.8B
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's portfolio of
Highlights
KNSA's net income has surged by 61% since the previous quarter
The EPS has surged by 60% since the previous quarter
KNSA's quick ratio is up by 12% QoQ but it is down by 11% YoY
KNSA's gross margin is down by 2.3% YoY
Key stats
What are the main financial stats of KNSA
Market
Valuations
Earnings
Shares outstanding
72.97M
Market cap
$1.95B
Enterprise value
$1.8B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.24
Price to sales (P/S)
4.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.75
Revenue
$481.17M
Gross profit
$412.97M
Operating income
-$15.8M
Net income
-$16.95M
EBIT
-$6.31M
EBITDA
-$1.55M
Free cash flow
$43.76M
Per share
Balance sheet
Liquidity
EPS
-$0.24
EPS diluted
-$0.25
Free cash flow per share
$0.6
Book value per share
$6.3
Revenue per share
$6.62
TBVPS
$8.03
Total assets
$599.33M
Total liabilities
$141.84M
Debt
$9.92M
Equity
$457.49M
Working capital
$258.64M
Debt to equity
0.02
Current ratio
3.66
Quick ratio
3.17
Net debt/EBITDA
95.29
Margins
Efficiency
Dividend
EBITDA margin
-0.3%
Gross margin
85.8%
Net margin
-3.5%
Operating margin
-3.3%
Return on assets
-3%
Return on equity
-3.8%
Return on invested capital
-1.9%
Return on capital employed
-1.3%
Return on sales
-1.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KNSA stock price
How has the Kiniksa Pharmaceuticals stock price performed over time
Intraday
-0.19%
1 week
-3.68%
1 month
37.17%
1 year
31.89%
YTD
35.09%
QTD
20.31%
Financial performance
How have Kiniksa Pharmaceuticals's revenue and profit performed over time
Revenue
$481.17M
Gross profit
$412.97M
Operating income
-$15.8M
Net income
-$16.95M
Gross margin
85.8%
Net margin
-3.5%
KNSA's operating margin has surged by 69% since the previous quarter and by 67% year-on-year
The net margin has surged by 66% since the previous quarter
KNSA's operating income has surged by 65% since the previous quarter and by 48% year-on-year
KNSA's net income has surged by 61% since the previous quarter
Price vs fundamentals
How does KNSA's price correlate with its fundamentals
Growth
What is Kiniksa Pharmaceuticals's growth rate over time
Valuation
What is Kiniksa Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.24
P/S
4.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.75
The EPS has surged by 60% since the previous quarter
KNSA's price to book (P/B) is 21% higher than its 5-year quarterly average of 3.5 and 21% higher than its last 4 quarters average of 3.5
Kiniksa Pharmaceuticals's equity has increased by 6% YoY and by 4.3% from the previous quarter
The stock's price to sales (P/S) is 74% less than its 5-year quarterly average of 15.4 but 6% more than its last 4 quarters average of 3.8
Kiniksa Pharmaceuticals's revenue has surged by 59% YoY and by 14% QoQ
Efficiency
How efficient is Kiniksa Pharmaceuticals business performance
The return on sales has surged by 85% since the previous quarter and by 82% year-on-year
KNSA's ROIC has soared by 83% from the previous quarter and by 72% YoY
Kiniksa Pharmaceuticals's return on assets has surged by 62% QoQ
Kiniksa Pharmaceuticals's return on equity has surged by 62% QoQ
Dividends
What is KNSA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KNSA.
Financial health
How did Kiniksa Pharmaceuticals financials performed over time
KNSA's total liabilities has surged by 62% year-on-year
The company's total assets rose by 15% YoY and by 3.2% QoQ
The debt is 98% smaller than the equity
The debt to equity has contracted by 33% YoY
The debt has declined by 18% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.